Therapy features of premenstrual syndrome in women with endometriosis

In: Reproductive Endocrinology · 2014 · vol. 0(17) , pp. 80 · doi:10.18370/2309-4117.2014.17.80-86 · W1914345474
article OA: diamond CC0
AI-generated summary by claude@2026-06, 2026-06-13

Magnicum treatment taken during the luteal phase for three months showed comparable effectiveness to dydrogesterone in managing premenstrual syndrome symptoms in women with endometriosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

AI-generated deep summary by claude@2026-06, 2026-06-13 · read from full text

This study evaluated treatment approaches for premenstrual syndrome in 45 reproductive-age women with moderate premenstrual syndrome severity and endometriosis, comparing Magnicum (magnesium) regimens—1 or 2 tablets three times daily from cycle day 14 to 28 for three months—against dydrogesterone. The authors reported that the Magnicum regimens were comparable in effectiveness to dydrogesterone, with particular benefit noted for the edematous form and certain neuropsychiatric and cephalgic symptoms. A key limitation stated in the abstract is that the trial focused on moderate severity and relatively short treatment duration (three months), without broader details on study design beyond the comparison. This paper is centrally about endometriosis — it tests magnesium-based Magnicum therapy for premenstrual syndrome specifically in women with endometriosis.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

A study on the effectiveness of treatment of premenstrual syndrome in patients with endometriosis was performed. It included 45 women of reproductive age from 19 to 40 years with moderate severity of premenstrual syndrome. Authors of this study suggested that treatment regimens 1 or 2 tablets Magnicum 3 times a day from the 14th to the 28th day of the menstrual cycle for three months were comparable in effectiveness with dydrogesterone treatment, especially for the edematous form and some symptoms of neuropsychiatric and cephalgic form of premenstrual syndrome.
Full text 2,496 characters · extracted from oa-doi-fallback · click to expand
Therapy features of premenstrual syndrome in women with endometriosis DOI: https://doi.org/10.18370/2309-4117.2014.17.80-86Keywords: premenstrual syndrome, endometriosis, magnesium, vitamin B6, MagnicumAbstract A study on the effectiveness of treatment of premenstrual syndrome in patients with endometriosis was performed. It included 45 women of reproductive age from 19 to 40 years with moderate severity of premenstrual syndrome. Authors of this study suggested that treatment regimens 1 or 2 tablets Magnicum 3 times a day from the 14th to the 28th day of the menstrual cycle for three months were comparable in effectiveness with dydrogesterone treatment, especially for the edematous form and some symptoms of neuropsychiatric and cephalgic form of premenstrual syndrome. References - Tatarchuk, T.F. Ventskovskaya, I.B. Shevchuk, T.V. «Premenstrual syndrome is an interdisciplinary problem.» Art of treatment,4(010) (2004):36-43. - Peresada, O.A. «Premenstrual syndrome: pathogenesis, clinical manifestations, treatment.» Medical News,8(2010):15-18. - Prilepskaya, V.N. Mezhevitinova, E.A. Sasunova, R.A. Ivanova, E.V. «Role of magnesium in the pathogenesis of premenstrual syndrome.» Russian Obstetrician and Gynecologist Gazette,3(2012). - Mayorov, M.V. Zhuchenko, S.I. «Using of magnesium drugs in outpatient gynecology.» Medical aspects of women’s health,1(2011):14 -18. - Gonda, X. Telek, T. Juhasz, G. Lazary, J. Vargha, A. Bagdy, G. «Patterns of mood changes throughout the reproductive cycle in healthy women without premenstrual dysphoric disorders.» Prog. Neuropsychopharmacol. Biol. Psychiatry,32(8)(2008):1782-1788. Downloads Published How to Cite Issue Section License Copyright (c) 2014 Н. Ф. Захаренко, В. П. Ковбасий, И. П. Маноляк This work is licensed under a Creative Commons Attribution 4.0 International License. Authors who publish with this journal agree to the following terms: - Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. - Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

openalex
last seen: 2026-06-04T00:00:01.174412+00:00
License: CC0 · commercial use OK